Data protection Impressum

Oncology

EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.

Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment

6 May 2024

Researchers at the EPFL have engineered lab-grown mini-colons that replicate the development of colorectal tumors with high fidelity.

EPFL scientists create lab-grown mini-colons to advance colorectal cancer research

29 April 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (March 2024)

26 March 2024

SmellRS is developing an ambitious and innovative technology for the early detection of Alzheimer's disease and the restoration of the sense of smell.

FONGIT Innovation Fund backs HeroSupport and SmellRS to advance healthcare innovation

4 March 2024

Onward Therapeutics’ move marks a critical transition for the company into the clinical stage, solidifying its role in developing innovative cancer treatments.

Onward Therapeutics enters clinical phase with innovative cancer immunotherapy

30 January 2024

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.

Cellestia Biotech receives CHF 2 million for its pioneering GvHD prevention therapy

23 January 2024

Novochizol technology quantitatively transforms single linear chitosan molecules into cross-linked, uniformly sized nanospheres.

EPFL and Novochizol to collaborate on designing more efficient immunotherapies

2 November 2023

Established in the canton of Valais since 1989, Debiopharm is building a full-scale research and innovation campus in Martigny.

Debiopharm invests CHF 30 million in Valais amidst workforce surge

26 October 2023

From left to right: Prof. Han (Professor of Yonsei Cancer Center), Dr. Chun (CSO of Oncosoft), Prof. Dong Wook Kim (Clinical Professor, Yonsei Cancer Center), Laura Acosta (Swiss Embassy Representative), Prof. Ik Jae Lee (Director of Heavy Ion Therapy, Yonsei Cancer Center), Dr. Christina Vallgren (CEO of Terapet), Herve Duffour (Sales and Marketing director of Terapet), Prof. Jin Sung Kim (Chief Medical Physicist of Yonsei Cancer Center & CEO of Oncosoft).

Terapet enters partnership with Korean entities for its breakthrough cancer therapy device

18 October 2023

The third building of the site was inaugurated in the presence (from left to right) of Stéphane Coppey, the President of the City of Monthey, Christophe Darbellay, Head of the Department of Economy and Education, and Jean-Marc Tornare, President of BioArk.

BioArk Monthey’s third building signifies exponential growth in the life sciences sector

16 October 2023

1 2 3 4 5 6 7 … 9